Literature DB >> 19173277

Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.

Shunsuke Ura1, Masao Honda, Taro Yamashita, Teruyuki Ueda, Hajime Takatori, Ryuhei Nishino, Hajime Sunakozaka, Yoshio Sakai, Katsuhisa Horimoto, Shuichi Kaneko.   

Abstract

UNLABELLED: MicroRNA (miRNA) plays an important role in the pathology of various diseases, including infection and cancer. Using real-time polymerase chain reaction, we measured the expression of 188 miRNAs in liver tissues obtained from 12 patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and 14 patients with hepatitis C virus (HCV)-related HCC, including background liver tissues and normal liver tissues obtained from nine patients. Global gene expression in the same tissues was analyzed via complementary DNA microarray to examine whether the differentially expressed miRNAs could regulate their target genes. Detailed analysis of the differentially expressed miRNA revealed two types of miRNA, one associated with HBV and HCV infections (n = 19), the other with the stage of liver disease (n = 31). Pathway analysis of targeted genes using infection-associated miRNAs revealed that the pathways related to cell death, DNA damage, recombination, and signal transduction were activated in HBV-infected liver, and those related to immune response, antigen presentation, cell cycle, proteasome, and lipid metabolism were activated in HCV-infected liver. The differences in the expression of infection-associated miRNAs in the liver correlated significantly with those observed in Huh7.5 cells in which infectious HBV or HCV clones replicated. Out of the 31 miRNAs associated with disease state, 17 were down-regulated in HCC, which up-regulated cancer-associated pathways such as cell cycle, adhesion, proteolysis, transcription, and translation; 6 miRNAs were up-regulated in HCC, which down-regulated anti-tumor immune response.
CONCLUSION: miRNAs are important mediators of HBV and HCV infection as well as liver disease progression, and therefore could be potential therapeutic target molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19173277     DOI: 10.1002/hep.22749

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  156 in total

1.  Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.

Authors:  Zehra Oksuz; Mehmet Sami Serin; Engin Kaplan; Aylin Dogen; Seda Tezcan; Gonul Aslan; Gurol Emekdas; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.

Authors:  Luisa Novellino; Riccardo L Rossi; Ferruccio Bonino; Daniela Cavallone; Sergio Abrignani; Massimiliano Pagani; Maurizia R Brunetto
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

Review 3.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

Review 4.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

5.  miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.

Authors:  Kevin Beezhold; Jia Liu; Hong Kan; Terry Meighan; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

Review 6.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

Review 7.  Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.

Authors:  Zdenko Herceg; Marie-Pierre Lambert; Karin van Veldhoven; Christiana Demetriou; Paolo Vineis; Martyn T Smith; Kurt Straif; Christopher P Wild
Journal:  Carcinogenesis       Date:  2013-06-07       Impact factor: 4.944

8.  Role natural killer group 2D-ligand interactions in hepatitis B infection.

Authors:  Teresa Pollicino; Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-04-28

Review 9.  Emerging role of microRNAs in liver diseases.

Authors:  Shashi Bala; Miguel Marcos; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 10.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.